Mucosal Healing Is Associated With the Reduced Disabling Disease in Crohn's Disease

被引:17
|
作者
Huang, Shanshan [1 ]
Li, Li [1 ]
Ben-Horin, Shomron [1 ,2 ,3 ]
Mao, Ren [1 ]
Lin, Sinan [1 ]
Qiu, Yun [1 ]
Feng, Rui [1 ]
He, Yao [1 ]
Chen, Baili [1 ]
Zeng, Zhirong [1 ]
Chen, Minhu [1 ]
Zhang, Shenghong [1 ]
机构
[1] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Gastroenterol, Guangzhou, Guangdong, Peoples R China
[2] Tel Aviv Univ, Dept Gastroenterol, Sheba Med Ctr, Tel Aviv, Israel
[3] Tel Aviv Univ, Sackler Sch Med, Tel Aviv, Israel
基金
中国国家自然科学基金;
关键词
INFLAMMATORY-BOWEL-DISEASE; THERAPY; BUDESONIDE; PREDICTORS; MANAGEMENT; MESALAMINE; REMISSION; CONSENSUS; OUTCOMES;
D O I
10.14309/ctg.0000000000000015
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
OBJECTIVES: Mucosal healing (MH) is the goal of the "treat to target" strategy in Crohn's disease (CD), which seeks to prevent disability. However, evidence is limited regarding whether achieving MH can reduce disability in CD. We aimed to estimate the probability of disabling disease and to investigate the association between MH and disabling disease in CD. METHODS: This was a retrospective case-control study of 319 consecutive CD patients. The primary outcome was disabling disease occurrence (defined as surgery, hospitalizations, steroid dependency, or disease complications). The secondary endpoint was disabling disease recurrence. The Kaplan-Meier method and Cox proportional hazards model were used to calculate cumulative rates and for multivariate analysis, respectively. RESULTS: Of 319 CD patients (median follow-up time: 42.4 months, interquartile range: 24.7-60.0 months), 105 (32.9%) progressed to disabling disease and 20 (6.3%) had the recurrence of disabling disease. The cumulative rates of disabling disease were 11.3%, 30.2%, and 44.9% at 1, 3, and 5 years, respectively, after diagnosis. MH was associated with a significantly lower frequency of surgery, new penetrating event, and new stenosis (P = 0.004, P= 0.001, P= 0.002, respectively). Univariate and multivariate analyses revealed that MH was an independent protective factor of disabling disease occurrence (hazard ratio: 0.166, 95% confidence interval: 0.084-0.329). CONCLUSIONS: Disabling disease was common in Chinese CD patients and increased during follow-up. Moreover, MH was significantly associated with a reduced occurrence of disabling disease in CD.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Mucosal healing in Crohn's disease
    Walker-Smith, JA
    [J]. GASTROENTEROLOGY, 1998, 114 (02) : 419 - 420
  • [2] Fungi in Crohn's disease and mucosal healing
    Hindson, Jordan
    [J]. NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2021, 18 (05) : 285 - 285
  • [3] Fungi in Crohn’s disease and mucosal healing
    Jordan Hindson
    [J]. Nature Reviews Gastroenterology & Hepatology, 2021, 18 : 285 - 285
  • [4] The use of methotrexate is associated with mucosal healing in Crohn's disease.
    Panaccione, R
    [J]. GASTROENTEROLOGY, 2005, 128 (04) : A49 - A49
  • [5] MUCOSAL HEALING REDUCED THE OCCURRENCE AND RECURRENCE OF CLINICAL DISABILITY IN CROHN'S DISEASE
    Huang, Shanshan
    Zhang, Shenghong
    Chen, Minhu
    [J]. GUT, 2018, 67 : A78 - A79
  • [6] High Infliximab Trough Levels are Associated With Mucosal Healing in Crohn's Disease
    Van Moerkercke, Wouter
    Ackaert, Chloe
    Compernolle, Griet
    Jurgens, Matthias
    Cleynen, Isabelle
    Van Assche, Gert A.
    Rutgeerts, Paul J.
    Gils, Ann
    Vermeire, Severine
    [J]. GASTROENTEROLOGY, 2010, 138 (05) : S60 - S60
  • [7] Multiomic features associated with mucosal healing and inflammation in paediatric Crohn's disease
    Taylor, Henry
    Serrano-Contreras, Jose Ivan
    McDonald, Julie A. K.
    Epstein, Jenny
    Fell, J. M.
    Seoane, Rocio C.
    Li, Jia V.
    Marchesi, Julian R.
    Hart, Ailsa L.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2020, 52 (09) : 1491 - 1502
  • [8] Mucosal healing in Crohn's disease patients is associated with reduction in hospitalizations and surgeries
    Rutgeerts, P
    Malchow, H
    Vatn, MH
    Yan, SK
    Bala, M
    Van Deventer, S
    [J]. GASTROENTEROLOGY, 2002, 123 (01) : 43 - 43
  • [9] Visceral Fat Is Associated With Mucosal Healing of Infliximab Treatment in Crohn's Disease
    Shen, Weisong
    Cao, Lei
    Li, Yi
    Cai, Xingchen
    Ge, Yuanyuan
    Zhu, Weiming
    [J]. DISEASES OF THE COLON & RECTUM, 2018, 61 (06) : 706 - 712
  • [10] Mucosal healing in Crohn's disease: new insights
    Cucchiara, Salvatore
    D'Arcangelo, Giulia
    Isoldi, Sara
    Aloi, Marina
    Stronati, Laura
    [J]. EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2020, 14 (05) : 335 - 345